Search

Your search keyword '"Cutlip, Donald E"' showing total 1,023 results
Start Over Author "Cutlip, Donald E"
1,023 results on '"Cutlip, Donald E"'

1. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

Author

Gustafsson, Finn, Petrie, Mark C., Komtebedde, Jan, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G.F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Solomon, Scott D., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

3. Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials

Author

Litwin, Sheldon E., Komtebedde, Jan, Borlaug, Barry A., Kaye, David M., Hasenfuβ, Gerd, Kawash, Rami, Hoendermis, Elke, Hummel, Scott L., Cikes, Maja, Gustafsson, Finn, Chung, Eugene S., Mohan, Rajeev C., Sverdlov, Aaron L., Swarup, Vijendra, Winkler, Sebastian, Hayward, Christopher S., Bergmann, Martin W., Bugger, Heiko, McKenzie, Scott, Nair, Ajith, Rieth, Andreas, Burkhoff, Daniel, Cutlip, Donald E., Solomon, Scott D., van Veldhuisen, Dirk J., Leon, Martin B., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

4. Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., Reddy, Vivek Y., Komtebedde, Jan, Wegerich, Stephan W., Sekaric, Jadranka, Swarup, Vijay, Walton, Antony, Laurent, Gabriel, Chetcuti, Stanley, Rademann, Matthias, Bergmann, Martin, McKenzie, Scott, Bugger, Heiko, Bruno, Raphael Romano, Herrmann, Howard C., Nair, Ajith, Gupta, Deepak K., Lim, Scott, Kapadia, Samir, Gordon, Robert, Vanderheyden, Marc, Noel, Thomas, Bailey, Steven, Gertz, Zachary M., Trochu, Jean-Noël, Cutlip, Donald E., Leon, Martin B., Solomon, Scott D., van Veldhuisen, Dirk J., Auricchio, Angelo, and Shah, Sanjiv J.

Published
2023
Full Text
View/download PDF

5. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction

Author

Litwin, Sheldon E., Komtebedde, Jan, Hu, Mo, Burkhoff, Daniel, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Gorter, Thomas M., Demers, Catherine, Shetty, Ranjith, Lewis, Gregory, Starling, Randall C., Patel, Sanjay, Gupta, Deepak K., Morsli, Hakim, Penicka, Martin, Cikes, Maja, Gustafsson, Finn, Silvestry, Frank E., Rowin, Ethan J., Cutlip, Donald E., Leon, Martin B., Kitzman, Dalane W., Kleber, Franz X., and Shah, Sanjiv J.

Published
2023
Full Text
View/download PDF

7. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

8. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose

Author

Gibson, C. Michael, Mack, Michael J., Lee, Victoria T., Schneider, David J., Sellke, Frank W., Ohman, E. Magnus, Thourani, Vinod H., Doros, Gheorghe, Kroger, Hans, Cutlip, Donald E., and Deliargyris, Efthymios N.

Published
2022
Full Text
View/download PDF

9. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., primary, Silvestry, Frank E., additional, Komtebedde, Jan, additional, Solomon, Scott D., additional, Hasenfuß, Gerd, additional, Litwin, Sheldon E., additional, Borlaug, Barry A., additional, Price, Matthew J., additional, Kawash, Rami, additional, Hummel, Scott L., additional, Cutlip, Donald E., additional, Leon, Martin B., additional, van Veldhuisen, Dirk J., additional, Rieth, Andreas J., additional, McKenzie, Scott, additional, Bugger, Heiko, additional, Mazurek, Jeremy A., additional, Kapadia, Samir R., additional, Vanderheyden, Marc, additional, Ky, Bonnie, additional, and Shah, Sanjiv J., additional

Published
2024
Full Text
View/download PDF

12. Causes of late mortality with dual antiplatelet therapy after coronary stents

Author

Mauri, Laura, Elmariah, Sammy, Yeh, Robert W, Cutlip, Donald E, Steg, P Gabriel, Windecker, Stephan, Wiviott, Stephen D, Cohen, David J, Massaro, Joseph M, D'Agostino, Ralph B, Braunwald, Eugene, and Kereiakes, Dean J

Subjects
Cancer, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Heart Disease - Coronary Heart Disease, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aspirin, Cause of Death, Drug Therapy, Combination, Drug-Eluting Stents, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Neoplasms, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Pyridines, Treatment Outcome, Dual antiplatelet therapy, Mortality, Thienopyridine, DAPT Study Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsIn the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.Methods and resultsPatients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).ConclusionBleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer.Trial registrationclinicaltrials.gov Identifier: NCT00977938.

Published
2016

14. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease Consensus Definitions From Peripheral Academic Research Consortium (PARC)

Author

Patel, Manesh R, Conte, Michael S, Cutlip, Donald E, Dib, Nabil, Geraghty, Patrick, Gray, William, Hiatt, William R, Ho, Mami, Ikeda, Koji, Ikeno, Fumiaki, Jaff, Michael R, Jones, W Schuyler, Kawahara, Masayuki, Lookstein, Robert A, Mehran, Roxana, Misra, Sanjay, Norgren, Lars, Olin, Jeffrey W, Povsic, Thomas J, Rosenfield, Kenneth, Rundback, John, Shamoun, Fadi, Tcheng, James, Tsai, Thomas T, Suzuki, Yuka, Vranckx, Pascal, Wiechmann, Bret N, White, Christopher J, Yokoi, Hiroyoshi, and Krucoff, Mitchell W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Clinical Trials and Supportive Activities, Angioplasty, Atherectomy, Blood Vessel Prosthesis, Constriction, Pathologic, Diagnostic Imaging, Endarterectomy, Humans, Lower Extremity, Patient Outcome Assessment, Peripheral Arterial Disease, Quality of Life, Severity of Illness Index, Stents, Walking, amputation, foot, intermittent claudication, leg, myocardial infarction, stroke, myocardial infarction, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

The lack of consistent definitions and nomenclature across clinical trials of novel devices, drugs, or biologics poses a significant barrier to accrual of knowledge in and across peripheral artery disease therapies and technologies. Recognizing this problem, the Peripheral Academic Research Consortium, together with the U.S. Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, has developed a series of pragmatic consensus definitions for patients being treated for peripheral artery disease affecting the lower extremities. These consensus definitions include the clinical presentation, anatomic depiction, interventional outcomes, surrogate imaging and physiological follow-up, and clinical outcomes of patients with lower-extremity peripheral artery disease. Consistent application of these definitions in clinical trials evaluating novel revascularization technologies should result in more efficient regulatory evaluation and best practice guidelines to inform clinical decisions in patients with lower extremity peripheral artery disease.

Published
2015

17. Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)

Author

Waksman, Ron, primary, Pahuja, Mohit, additional, van Diepen, Sean, additional, Proudfoot, Alastair G., additional, Morrow, David, additional, Spitzer, Ernest, additional, Nichol, Graham, additional, Weisfeldt, Myron L., additional, Moscucci, Mauro, additional, Lawler, Patrick R., additional, Mebazaa, Alexandre, additional, Fan, Eddy, additional, Dickert, Neal W., additional, Samsky, Marc, additional, Kormos, Robert, additional, Piña, Ileana L., additional, Zuckerman, Bram, additional, Farb, Andrew, additional, Sapirstein, John S., additional, Simonton, Charles, additional, West, Nick E.J., additional, Damluji, Abdulla A., additional, Gilchrist, Ian C., additional, Zeymer, Uwe, additional, Thiele, Holger, additional, Cutlip, Donald E., additional, Krucoff, Mitchell, additional, and Abraham, William T., additional

Published
2023
Full Text
View/download PDF

19. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Jr., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Sr., Pocock, Stuart J., Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

20. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations

Author

Ybarra, Luiz F., Rinfret, Stéphane, Brilakis, Emmanouil S., Karmpaliotis, Dimitri, Azzalini, Lorenzo, Grantham, J. Aaron, Kandzari, David E., Mashayekhi, Kambis, Spratt, James C., Wijeysundera, Harindra C., Ali, Ziad A., Buller, Christopher E., Carlino, Mauro, Cohen, David J., Cutlip, Donald E., De Martini, Tony, Di Mario, Carlo, Farb, Andrew, Finn, Aloke V., Galassi, Alfredo R., Gibson, C. Michael, Hanratty, Colm, Hill, Jonathan M., Jaffer, Farouc A., Krucoff, Mitchell W., Lombardi, William L., Maehara, Akiko, Magee, P.F. Adrian, Mehran, Roxana, Moses, Jeffrey W., Nicholson, William J., Onuma, Yoshinobu, Sianos, Georgios, Sumitsuji, Satoru, Tsuchikane, Etsuo, Virmani, Renu, Walsh, Simon J., Werner, Gerald S., Yamane, Masahisa, Stone, Gregg W., Rinfret, Stéphane, and Stone, Gregg W.

Published
2021
Full Text
View/download PDF

23. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System

Author

Cutlip, Donald, Allaqaband, Suhail, Caputo, Ronald, Beohar, Nirat, Brown, David, Garratt, Kirk, Jauhar, Rajiv, George, Jon, Varghese, Vincent, Huth, Mark, Larrain, German, Lee, Tommy, Malik, Amir, Martin, Scott, McGarry, Thomas, Phillips, Charles, Shah, Alpesh, Stoler, Robert, Ball, Michael, Price, R. Jeffrey, Rossi, Joseph, Taylor, Charles, Tolleson, Thaddeus, Nicholson, William, Kesanakurthy, Srinivas, Shoukfeh, Mohammad, Finn, Aloke, Devireddy, Chandanreddy, Shoultz, Charles, Robbins, Mark, Kiesz, Radoslaw, Menon, Pramod, Weilenmann, Daniel, Sievert, Horst, Erglis, Andrejs, Stankovic, Goran, Berland, Jacques, Delarche, Nicolas, Hirsch, Jean Lou, Maillard, Luc, Shayne, John, Serra, Antonio, Fernandez-Ortiz, Antonio, Monassier, Jean-Pierre, Silber, Sigmund, Cutlip, Donald E., Garratt, Kirk N., Novack, Victor, Barakat, Mark, Meraj, Perwaiz, and Popma, Jeffrey J.

Published
2017
Full Text
View/download PDF

26. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure

Author

Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G. F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean-Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean-Noël, Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., and Cardiovascular Centre (CVC)

Subjects
Male, Cardiac Catheterization, Pulmonary Circulation, hypertension, pulmonary, hypertension, pulmonary, heart failure, EXERCISE, PRESSURE, Article, Physiology (medical), therapeutics, Humans, Heart Atria, lung diseases, OUTCOMES, REST, Stroke Volume, clinical trial, TIME, Treatment Outcome, PRESERVED EJECTION FRACTION, Female, vascular diseases, Cardiology and Cardiovascular Medicine, INTERATRIAL SHUNT
Abstract

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004). Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.

Published
2022

28. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study

Author

Généreux, Philippe, Kumsars, Indulis, Schneider, Joel E., Lesiak, Maciej, Redfors, Björn, Cornelis, Kristoff, Selmon, Matthew R., Dens, Jo, Hoye, Angela, Metzger, D. Christopher, Muyldermans, Luc, Slagboom, Ton, Francese, Dominic P., Ayele, Girma Minalu, Laak, Linda L., Bartorelli, Antonio L., Cutlip, Donald E., Kaplan, Aaron V., and Leon, Martin B.

Published
2016
Full Text
View/download PDF

32. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy

Author

Kereiakes, Dean J., Yeh, Robert W., Massaro, Joseph M., Driscoll-Shempp, Priscilla, Cutlip, Donald E., Steg, P. Gabriel, Gershlick, Anthony H., Darius, Harald, Meredith, Ian T., Ormiston, John, Tanguay, Jean-François, Windecker, Stephan, Garratt, Kirk N., Kandzari, David E., Lee, David P., Simon, Daniel I., Iancu, Adrian Corneliu, Trebacz, Jaroslaw, and Mauri, Laura

Published
2015
Full Text
View/download PDF

33. Regional and physician specialty–associated variations in the medical management of atherosclerotic renal–artery stenosis

Author

Folt, David A., Evans, Kaleigh L., Brahmandam, Sravya, He, Wencan, Brewster, Pamela S., Yu, Shipeng, Murphy, Timothy P., Cutlip, Donald E., Dworkin, Lance D., Jamerson, Kenneth, Henrich, William, Kalra, Philip A., Tobe, Sheldon, Thomson, Ken, Holden, Andrew, Rayner, Brian L., Grinfeld, Liliana, Haller, Steven T., and Cooper, Christopher J.

Published
2015
Full Text
View/download PDF

34. Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease: The CLEVER Study

Author

Murphy, Timothy P., Cutlip, Donald E., Regensteiner, Judith G., Mohler, Emile R., III, Cohen, David J., Reynolds, Matthew R., Massaro, Joseph M., Lewis, Beth A., Cerezo, Joselyn, Oldenburg, Niki C., Thum, Claudia C., Jaff, Michael R., Comerota, Anthony J., Steffes, Michael W., Abrahamsen, Ingrid H., Goldberg, Suzanne, and Hirsch, Alan T.

Published
2015
Full Text
View/download PDF

36. A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions

Author

Généreux, Philippe, Kumsars, Indulis, Lesiak, Maciej, Kini, Annapoorna, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.

Published
2015
Full Text
View/download PDF

40. Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study

Author

Mihatov, Nino, primary, Secemsky, Eric A., additional, Kereiakes, Dean J., additional, Steg, P. Gabriel, additional, Cutlip, Donald E., additional, Kirtane, Ajay J., additional, Mehran, Roxana, additional, Zhao, Bokai, additional, Song, Yang, additional, Gibson, C. Michael, additional, and Yeh, Robert W., additional

Published
2022
Full Text
View/download PDF

48. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Hai, Mary T. Thanh, Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

50. 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)

Author

Gada, Hemal, Kirtane, Ajay J., Newman, William, Sanz, Mark, Hermiller, James B., Mahaffey, Kenneth W., Cutlip, Donald E., Sudhir, Krishnankutty, Hou, Liming, Koo, Kai, and Stone, Gregg W.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results